A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial

References

• Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, Long L, Luo L, Li Y, Leung GM, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Eurosurveillance. 2017;22(50): 16–6. doi:10.2807/1560-7917.ES.2017.22.50.16-00824.
   Web of Science ®Google Scholar
• Abzug MJ. The enteroviruses: problems in need of treatments. J Infect. 2014;68(Suppl 1):S108–14. doi:10.1016/j.jinf.2013.09.020.
   PubMedGoogle Scholar
• Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28. doi:10.1056/NEJMoa1304923.
   PubMed Web of Science ®Google Scholar
• Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37. doi:10.1056/NEJMoa1303224.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–32. doi:10.1016/s0140-6736(13)61049-1.
   PubMed Web of Science ®Google Scholar
• Fan S, Liao Y, Jiang G, Wang L, Zhao H, Yu L, Xu X, Li D, Zhang Y, Li Q, et al. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally. Vaccine. 2021;39(3):596–604. doi:10.1016/j.vaccine.2020.11.070.
   PubMed Web of Science ®Google Scholar
• Chen K, Li C, Wang Y, Shen Z, Guo Y, Li X, Zhang Y. Optimization of Vero cells grown on a polymer fiber carrier in a disposable bioreactor for inactivated Coxsackievirus A16 vaccine development. Vaccines. 2021;9(6):613. doi:10.3390/vaccines9060613.
   Web of Science ®Google Scholar
• Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165–68. doi:10.1016/j.vaccine.2013.02.053.
   PubMed Web of Science ®Google Scholar
• Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31(30):3104–09. doi:10.1016/j.vaccine.2013.04.026.
   PubMed Web of Science ®Google Scholar
• Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;35(36):4796–800. doi:10.1016/j.vaccine.2017.07.003.
   PubMed Web of Science ®Google Scholar
• Haber M, Lopman BA, Tate JE, Shi M, Parashar UD. A comparison of the test-negative and traditional case-control study designs with respect to the bias of estimates of rotavirus vaccine effectiveness. Vaccine. 2018;36(33):5071–76. doi:10.1016/j.vaccine.2018.06.072.
   PubMed Web of Science ®Google Scholar
• Araki K, Hara M, Shimanoe C, Nishida Y, Matsuo M, Tanaka K. Case-control study of Rotavirus vaccine effectiveness compared to test-negative controls or hospital controls. J Epidemiol. 2018;29(8):282–87. doi:10.2188/jea.JE20180054.
   PubMed Web of Science ®Google Scholar
• Shi M, An Q, Ainslie KEC, Haber M, Orenstein WA. A comparison of the test-negative and the traditional case-control study designs for estimation of influenza vaccine effectiveness under nonrandom vaccination. BMC Infect Dis. 2017;17(1):757. doi:10.1186/s12879-017-2838-2.
   PubMedGoogle Scholar
• Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668–74. doi:10.1016/j.vaccine.2011.10.018.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Meng FY, Mao Q, Li J-X, Wang H, Liang Z-L, Zhang Y-T, Gao F, Chen Q-H, Hu Y, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccines Immunother. 2014;10(5):1366–72. doi:10.4161/hv.28397.
   PubMed Web of Science ®Google Scholar
• Zhu W, Jin P, Li JX, Zhu FC, Liu P. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Rev Vaccines. 2017;16(9):945–49. doi:10.1080/14760584.2017.1335603.
   PubMed Web of Science ®Google Scholar
• Jin P, Li J, Zhang X, Meng F, Zhou Y, Yao X, Gan Z, Zhu F. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. Hum Vaccines Immunother. 2016;12(4):916–21. doi:10.1080/21645515.2015.1118595.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wei M, Jin P, Li J, Zhu F. An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial. Hum Vaccines Immunother. 2021;17(7):2101–06. doi:10.1080/21645515.2020.1859900.
   PubMed Web of Science ®Google Scholar
• Sadoff JC, Wittes J. Correlates, surrogates, and vaccines. J Infect Dis. 2007;196(9):1279–81. doi:10.1086/522432.
   PubMed Web of Science ®Google Scholar
• Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, et al. Case-Control vaccine effectiveness studies: preparation, design, and enrollment of cases and controls. Vaccine. 2017;35(25):3295–302. doi:10.1016/j.vaccine.2017.04.037.
   PubMed Web of Science ®Google Scholar
• Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, et al. Case-Control vaccine effectiveness studies: data collection, analysis and reporting results. Vaccine. 2017;35(25):3303–08. doi:10.1016/j.vaccine.2017.04.035.
   PubMed Web of Science ®Google Scholar
• Balasubramani GK, Zimmerman RK, Eng H, Lyons J, Clarke L, Nowalk MP. Comparison of local influenza vaccine effectiveness using two methods. Vaccine. 2021;39(8):1283–89. doi:10.1016/j.vaccine.2021.01.013.
   PubMed Web of Science ®Google Scholar
• Franke MF, Jerome JG, Matias WR, Ternier R, Hilaire IJ, Harris JB, Ivers LC. Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design. Vaccine. 2017;35(43):5819–27. doi:10.1016/j.vaccine.2017.09.025.
   PubMed Web of Science ®Google Scholar
• Follmann DA, Dodd L. Immune correlates analysis using vaccines from test negative designs. Biostatistics. 2020. doi:10.1093/biostatistics/kxaa037.
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184(5):345–53. doi:10.1093/aje/kww064.
   PubMed Web of Science ®Google Scholar